Less is more: potential breakthrough for treating hypertension with ultra low-dose combinations
A small but clinically important trial of a new ultra-low dose four-in-one pill to treat high blood pressure has produced remarkable results.
Every patient on the pilot trial conducted by The George Institute for Global Health saw their blood pressure levels drop to normal levels in just four weeks.
Professor Clara Chow, of The George Institute, said the results published in The Lancet were exciting but larger trials were needed to see if these high rates could be maintained and repeated.
Professor Chow, director of the Cardiovascular Division at The George Institute in Sydney, said: “Most people receive one medicine at a normal dose but that only controls blood pressure about half the time. In this small trial blood pressure control was achieved for everyone. Trials will now test whether this can be repeated and maintained long-term.
“Minimising side effects is important for long-term treatments – we didn’t see any issues in this trial, as you would hope with very low dose therapy, but this is the area where more long-term research is most needed.
“We know that high blood pressure is a precursor to stroke, diabetes and heart attack. The need for even lower blood pressure levels has been widely accepted in the last few years. So this could be an incredibly important step in helping to reduce the burden of disease globally.”
Hypertension or high blood pressure affects over four million people in Australia.
Over four weeks 18 patients in Sydney were either given a quadpill – a single capsule containing four of the most commonly used blood pressure-lowering drugs each at a quarter dose – or a placebo. This was then repeated for a further four weeks with the patients swapping their course of treatment.
Blood pressure levels were measured hourly over a 24 hour period at the end of each treatment, allowing researchers to significantly reduce the amount of patients normally required in a clinical trial.
- 100 per cent of patients on trial saw their blood levels drop below 140 over 90. Just 33 per cent of patients on the placebo achieved this rate.
- None of the patients experienced side effects commonly associated with hypertension lowering drugs, which can vary from swollen ankles to kidney abnormalities depending on the type of class of the drug.
Professor Chow said: “What makes these result every more exciting is that these four blood pressure medications are already in use. We are increasingly finding there are opportunities to treat many commons diseases hiding in plain sight. This ultimately means we will be able to deliver life changing medications much more quickly, and more affordably.”
Researchers at The George Institute are just about to commence a much larger trial into the quadpill which has been funded by the NHMRC. Find out more about the QUARTET project
The project was funded by The National Heart Foundation of Australia and the University of Sydney